| [1] |
|
| [2] |
Bolton-Maggs PHB, Langer JC, Iolascon A, et al. Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update[J]. Br J Haematol, 2012, 156(1): 37-49. DOI: 10.1111/j.1365-2141.2011.08921.x.
|
| [3] |
Vercellati C, Zaninoni A, Marcello AP, et al. Changing trends of splenectomy in hereditary spherocytosis: the experience of a reference Centre in the last 40 years[J]. Br J Haematol, 2022, 198(5): 912-915. DOI: 10.1111/bjh.18106.
|
| [4] |
Seims AD, Breckler FD, Hardacker KD, et al. Partial versus total splenectomy in children with hereditary spherocytosis[J]. Surgery, 2013, 154(4): 849-855. DOI: 10.1016/j.surg.2013.07.019.
|
| [5] |
Manciu S, Nae GA, Diaconu A, et al. Long-term evaluation of the outcomes of subtotal laparoscopic and robotic splenectomy in hereditary spherocytosis[J]. World J Surg, 2020, 44(7): 2220-2228. DOI: 10.1007/s00268-020-05485-3.
|
| [6] |
Vasilescu C, Stanciulea O, Tudor S, et al. Laparoscopic subtotal splenectomy in hereditary spherocytosis: to preserve the upper or the lower pole of the spleen?[J]. Surg Endosc, 2006, 20(5): 748-752. DOI: 10.1007/s00464-005-0429-6.
|
| [7] |
Manciu S, Matei E, Trandafir B. Hereditary spherocytosis-diagnosis, surgical treatment and outcomes. a literature review[J]. Chirurgia, 2017, 112(2): 110. DOI: 10.21614/chirurgia.112.2.110.
|
| [8] |
Vecchio R, Intagliata E, Ferla F, et al. Laparoscopic splenectomy in patients with hereditary spherocytosis: report on 12 consecutive cases[J]. Updates Surg, 2013, 65(4): 277-281. DOI: 10.1007/s13304-013-0236-x.
|
| [9] |
Güngör A, Yaralı N, Fettah A, et al. Hereditary spherocytosis: Retrospective evaluation of 65 children[J]. Turk J Pediatr, 2018, 60(3): 264-269. DOI: 10.24953/turkjped.2018.03.005.
|
| [10] |
|
| [11] |
Patel NY, Chilsen AM, Mathiason MA, et al. Outcomes and complications after splenectomy for hematologic disorders[J]. Am J Surg, 2012, 204(6): 1014-1020. DOI: 10.1016/j.amjsurg.2012.05.030.
|
| [12] |
Maskal S, Al Marzooqi R, Fafaj A, et al. Clinical and surgical outcomes of splenectomy for autoimmune hemolytic Anemia[J]. Surg Endosc, 2022, 36(8): 5863-5872. DOI: 10.1007/s00464-022-09116-x.
|
| [13] |
|
| [14] |
Gutiérrez Jomarrón I, López Rubio M, Morado Arias M, et al. Autoimmune haemolytic anaemias: a retrospective study of 93 patients[J]. Med Clin, 2020, 154(9): 331-337. DOI: 10.1016/j.medcle.2019.06.025.
|
| [15] |
Giudice V, Rosamilio R, Ferrara I, et al. Efficacy and safety of splenectomy in adult autoimmune hemolytic Anemia[J]. Open Med, 2016, 11(1): 374-380. DOI: 10.1515/med-2016-0068.
|
| [16] |
Cvetković Z, Pantić N, Cvetković M, et al. The role of the spleen and the place of splenectomy in autoimmune hemolytic anemia: a review of current knowledge[J]. Diagnostics, 2023, 13(18): 2891. DOI: 10.3390/diagnostics13182891.
|
| [17] |
Al-Samkari H, Shehata N, Lang-Robertson K, et al. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines[J]. Lancet Haematol, 2024, 11(3): e228-e239. DOI: 10.1016/S2352-3026(23)00377-0.
|
| [18] |
Al-Samkari H, Van Beers EJ, Kuo KHM, et al. The variable manifestations of disease in pyruvate kinase deficiency and their management[J]. Haematologica, 2020, 105(9): 2229-2239. DOI: 10.3324/haematol.2019.240846.
|
| [19] |
|
| [20] |
Grace RF, Barcellini W. Management of pyruvate kinase deficiency in children and adults[J]. Blood, 2020, 136(11): 1241-1249. DOI: 10.1182/blood.2019000945.
|
| [21] |
Grace RF, Bianchi P, van Beers EJ, et al. Clinical spectrum of pyruvate kinase deficiency: data from the pyruvate kinase deficiency natural history study[J]. Blood, 2018, 131(20): 2183-2192. DOI: 10.1182/blood-2017-10-810796.
|
| [22] |
Fattizzo B, Cavallaro F, Marcello APML, et al. Pyruvate kinase deficiency: current challenges and future prospects[J]. J Blood Med, 2022, 13: 461-471. DOI: 10.2147/jbm.s353907.
|
| [23] |
Rabinovich E, Pradhan K, Islam I, et al. Splenomegaly and response to splenectomy in immune thrombocytopenia[J]. J Clin Med, 2024, 13(13): 3712. DOI: 10.3390/jcm13133712.
|
| [24] |
Kojouri K, Vesely SK, Terrell DR, et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications[J]. Blood, 2004, 104(9): 2623-2634. DOI: 10.1182/blood-2004-03-1168.
|
| [25] |
Ghanima W, Godeau B, Cines DB, et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment[J]. Blood, 2012, 120(5): 960-969. DOI: 10.1182/blood-2011-12-309153.
|
| [26] |
Worrest T, Cunningham A, Dewey E, et al. Immune thrombocytopenic purpura splenectomy in the context of new medical therapies[J]. J Surg Res, 2020, 245: 643-648. DOI: 10.1016/j.jss.2019.06.092.
|
| [27] |
Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out[J]. Blood, 2018, 131(11): 1172-1182. DOI: 10.1182/blood-2017-09-742353.
|
| [28] |
Mageau A, Terriou L, Ebbo M, et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment[J]. American J Hematol, 2022, 97(1): 10-17. DOI: 10.1002/ajh.26378.
|
| [29] |
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia[J]. Blood Adv, 2019, 3(23): 3829-3866. DOI: 10.1182/bloodadvances.2019000966.
|
| [30] |
Weycker D, Hanau A, Hatfield M, et al. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis[J]. J Med Econ, 2020, 23(2): 184-192. DOI: 10.1080/13696998.2019.1669329.
|
| [31] |
Edgren G, Almqvist R, Hartman M, et al. Splenectomy and the risk of sepsis: a population-based cohort study[J]. Ann Surg, 2014, 260(6): 1081-1087. DOI: 10.1097/sla.0000000000000439.
|
| [32] |
Gonzalez-Porras JR, Escalante F, Pardal E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia[J]. European J Haematology, 2013, 91(3): 236-241. DOI: 10.1111/ejh.12146.
|
| [33] |
Chen FE, Ooi C, Ha SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients[J]. N Engl J Med, 2000, 343(8): 544-550. DOI: 10.1056/nejm200008243430804.
|
| [34] |
King AJ, Higgs DR. Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form of α-thalassemia[J]. Hematology Am Soc Hematol Educ Program, 2018, 2018(1): 353-360. DOI: 10.1182/asheducation-2018.1.353.
|
| [35] |
Musallam KM, Angastiniotis M, Eleftheriou A, et al. Cross-talk between available guidelines for the management of patients with beta-thalassemia major[J]. Acta Haematol, 2013, 130(2): 64-73. DOI: 10.1159/000345734.
|
| [36] |
广东省地中海贫血防治协会, 《中国实用儿科杂志》编辑委员会. 儿童非输血依赖型地中海贫血的诊治和管理专家共识[J]. 中国实用儿科杂志, 2018, 33(12): 929-934. DOI: 10.19538/j.ek2018120601. |
| [37] |
Taher AT, Musallam KM, Karimi M, et al. Contemporary approaches to treatment of beta-thalassemia intermedia[J]. Blood Rev, 2012, 26(Suppl 1): S24-S27. DOI: 10.1016/S0268-960X(12)70008-5.
|
| [38] |
Tantiworawit A, Dumnil S, Osataphan N, et al. The pros and cons of splenectomy in transfusion dependent thalassemia patient[J]. Blood, 2018, 132(Supplement 1): 4901. DOI: 10.1182/blood-2018-99-111684.
|
| [39] |
Jacob E. The pain experience of patients with sickle cell Anemia[J]. Pain Manag Nurs, 2001, 2(3): 74-83. DOI: 10.1053/jpmn.2001.26119.
|
| [40] |
Mechraoui A, Ithier G, Pages J, et al. Early splenectomy in a large cohort of children with sickle cell anemia: risks and consequences[J]. Haematologica, 2023, 108(12): 3409-3417. DOI: 10.3324/haematol.2022.282556.
|
| [41] |
Al-Salem AH. Indications and complications of splenectomy for children with sickle cell disease[J]. J Pediatr Surg, 2006, 41(11): 1909-1915. DOI: 10.1016/j.jpedsurg.2006.06.020.
|
| [42] |
Santos FPS, Tam CS, Kantarjian H, et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation[J]. Leuk Lymphoma, 2014, 55(1): 121-127. DOI: 10.3109/10428194.2013.794269.
|
| [43] |
Cervantes F. How I treat splenomegaly in myelofibrosis[J]. Blood Cancer J, 2011, 1(10): e37. DOI: 10.1038/bcj.2011.36.
|
| [44] |
Malato A, Rossi E, Tiribelli M, et al. Splenectomy in myelofibrosis: indications, efficacy, and complications[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(9): 588-595. DOI: 10.1016/j.clml.2020.04.015.
|
| [45] |
McLornan DP, Psaila B, Ewing J, et al. The management of myelofibrosis: a British society for haematology guideline[J]. Br J Haematol, 2024, 204(1): 136-150. DOI: 10.1111/bjh.19186.
|
| [46] |
Buesing KL, Tracy ET, Kiernan C, et al. Partial splenectomy for hereditary spherocytosis: a multi-institutional review[J]. J Pediatr Surg, 2011, 46(1): 178-183. DOI: 10.1016/j.jpedsurg.2010.09.090.
|
| [47] |
Rahman M, Mondal SK, Kabir AL, et al. Outcome of partial splenectomy for hypersplenism in children with thalassemia[J]. J Paediatr Surg Bangladesh, 2016, 6(2): 39-46. DOI: 10.3329/jpsb.v6i2.27748.
|
| [48] |
Roshdy MR, Botros M, Mokhles A, et al. Partial splenectomy versus total splenectomy in sickle cell disease: a systematic review and meta-analysis[J]. J Pediatr Surg, 2025, 60(2): 162058. DOI: 10.1016/j.jpedsurg.2024.162058.
|
| [49] |
Romboli A, Annicchiarico A, Morini A, et al. Laparoscopic partial splenectomy: a critical appraisal of an emerging technique. a review of the first 457 published cases[J]. J Laparoendosc Adv Surg Tech, 2021, 31(10): 1130-1142. DOI: 10.1089/lap.2020.0769.
|
| [50] |
Englum BR, Rothman J, Leonard S, et al. Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic Anemia[J]. J Pediatr Surg, 2016, 51(1): 122-127. DOI: 10.1016/j.jpedsurg.2015.10.028.
|